SPORE in Lung Cancer

描述（由申请人提供）：在过去40年中，肺癌的5年生存率与所有癌症的5年生存率的改善保持同步。然而，它仍然令人沮丧地低至-15%。5年生存率的提高是提高认识、更好的检测技术、更好地选择患者进行各种治疗选择以及选择性使用姑息性干预的结果。然而，肺癌死亡率仍然非常高，这是子孙后代判断我们有效防治这一疾病成功与否的基准。Moffitt癌症中心肺癌SPORE将1）阐明肺癌发生和肿瘤进展中关键分子的作用机制，并研究其对治疗效果的影响，2）前瞻性评估分子用于治疗和预防干预的临床效用。我们的最终目标是改变肺癌高危人群的护理标准。该孢子有五个转化研究项目，三个核心，发展研究计划和职业发展计划。 这些项目是： 1)E2 Fs对治疗效果的影响（Cress，Chen和Bepler） 2)RRM 1在肺癌管理中的作用（Bepler，Cress & Simon） 3)Src抑制剂在肺癌中的抗肿瘤机制（Haura，Cheng & Pledger） 4)肺癌的化学预防与Enzaeurin（Bepler & Alexandrow） 5)基于p53的小细胞肺癌疫苗（Gabrilovich & Antonia） 它们得到以下方面的支持： A）组织采购、病理学和生物信息学核心（Altiok & Fenstermacher） B）临床试验和生物统计学核心（Simon，Schell & Bepler） C）管理和患者倡导核心（Bepler，Cress & Quinn）。 该SPORE还拥有发展研究和职业发展计划。该SPORE将牢固地集成到H。李莫菲特癌症中心和研究所，一个独立的，NCI指定的综合癌症在坦帕，佛罗里达。

DESCRIPTION (provided by applicant): The 5-year survival from lung cancer has kept pace with the improvement in 5-year survival from all cancers over the last 40 years. Yet, it remains disappointingly low at -15%. This improvement in 5-year survival is a result of heightened awareness, better technology for detection, better selection of patients for various therapeutic options, and the selective use of palliative interventions. However, lung cancer mortality remains extraordinarily high, and it is the benchmark by which future generations will judge our success in effectively combating this disease. The Moffitt Cancer Center SPORE in Lung Cancer will 1) elucidate mechanisms of action of crucial molecules in lung carcinogenesis and tumor progression and investigate their impact on therapeutic efficacy and 2) prospectively assess the clinical utility of the molecules for therapeutic and prevention interventions. Our ultimate goal is to change the standard of care for people at risk for and with lung cancer. The SPORE has five translational research projects, three cores, a developmental research program, and a career development program. The projects are: 1) E2Fs Impact on Therapeutic Efficacy (Cress, Chen & Bepler) 2) RRM1 in the Management of Lung Cancer (Bepler, Cress & Simon) 3) Antitumor Mechanisms of Src Inhibitors in Lung Cancer (Haura, Cheng & Pledger) 4) Lung Cancer Chemoprevention with Enzastaurin (Bepler & Alexandrow) 5) p53-Based Vaccine for Small Cell Lung Cancer (Gabrilovich & Antonia) They are support by: A) Tissue Procurement, Pathology, and Bioinformatics Core (Altiok & Fenstermacher) B) Clinical Trials & Biostatistics Core (Simon, Schell & Bepler) C) Administration & Patient Advocacy Core (Bepler, Cress & Quinn). The SPORE also has Developmental Research & Career Development Programs. This SPORE will be firmly integrated into the H. Lee Moffitt Cancer Center and Research Institute, a free-standing, NCI designated Comprehensive Cancer in Tampa, Florida.